Accordingly, cells which were grown in serum-free medium and treated with a CCL2 neutralizing antibody or a CCR2 antagonist (RS504393) had significantly decreased proliferation of tumor cells compared with untreated control cells (134, 146). This evidence concerns the gene CCR2 and neoplasm.